The attempt to address the most menacing threat faced by mankind finds a hope. At Bugworks, our world class team aims to create a much needed respite to AMR through our broad spectrum anti-bacterial assets.
Saving mankind from the threat of AMR using our path-breaking discoveries
Know More
Bugworks one of four global companies exemplified in this latest AMR report from Access to Medicines Foundation
G7 health ministers make AMR an important facet of pandemic preparedness and vow to incentivise this space
Bugworks featured amongst the top 5 innovative Biotech companies to look out for in India by Pharmareg News.
Bugworks secures support from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
